

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-68. (Cancelled)

Claim 69. (Currently Amended): A method for stimulating CD8<sup>+</sup> T cells within a population of T cells to proliferate, comprising:

a) contacting a population of T cells with an anti-CD3 antibody or a CD3-binding fragment thereof, an anti-CD28 antibody or a CD28-binding fragment thereof, and an anti-CD9 antibody or a CD9-binding fragment thereof, under conditions appropriate for proliferation of the T cells;

b) separating the anti-CD3 antibody or the CD3-binding fragment thereof from the T cells and the anti-CD9 antibody or the CD9-binding fragment thereof and the anti-CD28 antibody or the CD28-binding fragment thereof;

c) monitoring proliferation of the T cells in response to continuing exposure to the anti-CD9 antibody or the CD9-binding fragment thereof and the anti-CD28 antibody or the CD28-binding fragment thereof; and

d) re-stimulating the T cells with ~~an~~ the anti-CD3 antibody or the CD3-binding fragment thereof, ~~and~~ the anti-CD9 antibody or the CD9-binding fragment thereof and the anti-CD28 antibody or the CD28-binding fragment thereof, when the rate of T cell proliferation has decreased to induce further proliferation of the T cells.

Claim 70. (Previously Presented): The method of claim 69, further comprising repeating steps (b)-(d) to produce a population of T cells increased in number of from about 100- to about 100,000-fold the original T cell population.

Claim 71. (Cancelled)

Appl. No. 09/183,055

Our Ref. No.: 36119.125US8

Amendment under 37 C.F.R. § 1.114

Claim 72. (Previously Presented): The method of claim 69, wherein said anti-CD3 antibody is a whole antibody.